Novartis Secures Exclusive Rights to Zonsen PepLib’s Radioligand Asset
Novartis (NYSE: NVS) announced it has secured exclusive global rights to an undisclosed peptide asset...
Boan Biosimilar Prolia Wins Bolivia Approval, Targets Global Markets
Shandong Boan Biotechnology Co., Ltd. (HKG: 6955) announced that BA6101, its biosimilar version of Amgen’s...
Johnson & Johnson Strikes Tariff Exemption Deal with Trump Administration
Johnson & Johnson (J&J, NYSE: JNJ) announced a voluntary agreement with the Trump Administration to...
Hybio Pharmaceutical Licenses Semaglutide to Vitamedic for Brazil Market
Hybio Pharmaceutical Co., Ltd (SHE: 300199) announced an out‑licensing agreement with Vitamedic Health Nutraceuticals (Brazil),...
Merck in Talks to Acquire Revolution Medicines for $28‑32 Billion in Oncology Push
Merck Sharp & Dohme Inc. (MSD, NYSE: MRK) is reportedly in advanced negotiations to acquire Revolution Medicines...
Genrix Bio’s GR1803 NDA Accepted for BCMA-Targeted Multiple Myeloma Therapy
Chongqing Genrix Biopharmaceutical Co., Ltd (SHA: 688443) announced that the conditional New Drug Application (NDA)...
RemeGen’s RC48 Wins Fourth Breakthrough Therapy Designation for Gastric Cancer Combo
RemeGen Ltd (SHA: 688331, HKG: 9995) announced that its core product, Disitamab Vedotin (RC48/Aidixi), has...
Merck Initiates Phase 3 Trial for Calderasib + KEYTRUDA QLEX in KRAS G12C NSCLC
Merck Sharp & Dohme Inc. (MSD, NYSE: MRK) announced the initiation of KANDLELIT‑007, a Phase 3 clinical...
Takeda Licenses Halozyme’s ENHANZE Technology for Vedolizumab in Global Deal
Takeda Pharmaceutical Company Limited (TYO: 4502, NYSE: TAK) announced a global collaboration and license agreement...
Hansoh Pharmaceutical’s Ameile Wins Fifth NMPA Indication for EGFR‑Mutated NSCLC
Hansoh Pharmaceutical Group Company Limited (HKG: 3692) announced that its core product, Ameile (almonertinib), has...
Eisai China and Xuanwu Hospital Forge Strategic Cooperation for Drug R&D
Eisai (TYO: 4523) China and Xuanwu Hospital of Capital Medical University officially signed a Strategic...
Imunopharm’s IM19 CAR‑T Wins NMPA IND for Second‑Line NHL Therapy
Beijing Imunopharm Technology Co., Ltd. announced that its independently developed CD19‑targeted CAR‑T cell therapy, IM19,...
InduPro Partners with Lilly on $950M Oncology Deal Using Proximity-Guided Platform
InduPro announced a global strategic collaboration, licensing agreement, and equity investment with Eli Lilly (NYSE:...
MediLink Licenses B7H3 ADC YL201 to Roche in $850 Million Global Deal
MediLink Therapeutics announced a collaboration and exclusive licensing agreement with Roche (SWX: ROG, OTCMKTS: RHHBY)...
Shanghai MicuRx’s Contezolid Patent Extended Through 2033, Securing Market Exclusivity
Shanghai MicuRx Pharmaceutical Co., Ltd (SHA: 688373) announced that the patent for its core product,...
Lilly’s Taltz-Zepbound Combo Meets Primary Endpoint in Psoriatic Arthritis
Eli Lilly (NYSE: LLY) announced positive topline results from the TOGETHER‑PsA open‑label Phase 3b trial evaluating...
NMPA Issues New Rules to Strengthen Pharmaceutical Contract Manufacturing Oversight
The National Medical Products Administration (NMPA) issued the “Announcement on Strengthening Supervision and Management of...
Betta Pharmaceuticals Partners with Westlake University on Pharma Innovation
Betta Pharmaceuticals Co., Ltd. (SHE: 300558) and Westlake University announced a strategic partnership to advance...
Viva Biotech and CMS Forge AI-Powered Drug Development Alliance
Viva Biotech (HKG: 1873) and China Medical System Holdings Limited (CMS; HKG: 0867, SGX: 8A8)...
Hisun and ECNU Forge AI Drug Discovery Partnership
Zhejiang Hisun Pharmaceutical Co., Ltd. (SHA: 600267) and East China Normal University (ECNU) announced a...